OMERS ADMINISTRATION Corp Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

OMERS ADMINISTRATION Corp increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 20.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,648 shares of the life sciences company’s stock after acquiring an additional 1,114 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Illumina were worth $888,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Meridiem Capital Partners LP purchased a new position in Illumina in the 4th quarter worth $12,712,000. Laurion Capital Management LP purchased a new position in Illumina in the 4th quarter worth $950,000. Integral Health Asset Management LLC purchased a new position in Illumina in the 4th quarter worth $5,345,000. Jacobs Levy Equity Management Inc. purchased a new position in Illumina in the 4th quarter worth $1,314,000. Finally, Focus Partners Wealth raised its position in Illumina by 36.3% in the 4th quarter. Focus Partners Wealth now owns 7,687 shares of the life sciences company’s stock worth $1,040,000 after purchasing an additional 2,046 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares of the company’s stock, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.17% of the stock is currently owned by insiders.

Illumina Trading Up 3.4%

Shares of ILMN opened at $83.62 on Friday. The firm’s 50-day moving average price is $78.48 and its 200-day moving average price is $111.12. The firm has a market capitalization of $13.23 billion, a price-to-earnings ratio of -10.89, a PEG ratio of 1.60 and a beta of 1.35. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the firm posted $0.98 EPS. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. Barclays decreased their target price on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a research report on Thursday, April 10th. Canaccord Genuity Group cut their price target on shares of Illumina from $92.00 to $87.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Guggenheim cut their price target on shares of Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $130.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.